Kezar Life Sciences, Inc.
KZR
$4.10
$0.051.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -78.63M | -83.74M | -95.78M | -98.57M | -101.33M |
| Total Depreciation and Amortization | 1.03M | 1.04M | 1.06M | 1.08M | 1.07M |
| Total Amortization of Deferred Charges | 354.00K | 259.00K | 252.00K | 246.00K | 240.00K |
| Total Other Non-Cash Items | 9.70M | 9.53M | 11.72M | 14.63M | 13.59M |
| Change in Net Operating Assets | -986.00K | -1.30M | 6.38M | 3.53M | 2.79M |
| Cash from Operations | -68.54M | -74.21M | -76.37M | -79.08M | -83.65M |
| Capital Expenditure | -37.00K | -29.00K | -19.00K | -137.00K | -1.51M |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 5.00K | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.80M | 80.46M | 84.58M | 79.21M | 81.57M |
| Cash from Investing | 73.76M | 80.43M | 84.56M | 79.08M | 80.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.30M | -- | -- | -- | -- |
| Issuance of Common Stock | 103.00K | 103.00K | 115.00K | 158.00K | 484.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.20M | 103.00K | 115.00K | 158.00K | 484.00K |
| Foreign Exchange rate Adjustments | -51.00K | -63.00K | 50.00K | 11.00K | 3.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.97M | 6.26M | 8.36M | 167.00K | -3.10M |